NCT04084860
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
Recruiting
PHASE2Ages 21–70InterventionalTreatmentNew York State Psychiatric InstituteInvestigator-initiated
~120 participants
Updated 2023-11-07 on ClinicalTrials.gov
What's tested:CI-581aCI-581bMBRPMET
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Daily occurrence of Heavy Drinking Days (HDD)
Measured over 12 weeks
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Elias Dakwar, MD · PRINCIPAL_INVESTIGATOR · NYSPI/Columbia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Daily occurrence of Heavy Drinking Days (HDD)12 weeks
Defined as \>4 drinks/day for men; \>3 drinks for women. Comparing this outcome between groups that receive CI-581a versus CI-581b, as well as between CI-581a groups.